Insight Molecular Diagnostics Inc. (IMDX)
NASDAQ: IMDX · Real-Time Price · USD
5.53
+0.08 (1.47%)
Mar 9, 2026, 1:14 PM EDT - Market open
IMDX Employees
As of December 31, 2024, Insight Molecular Diagnostics had 49 total employees, including 46 full-time and 3 part-time employees. The number of employees increased by 3 or 6.52% compared to the previous year.
Employees
49
Change (1Y)
3
Growth (1Y)
6.52%
Revenue / Employee
$89,837
Profits / Employee
-$1,240,367
Market Cap
177.88M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Myriad Genetics | 2,700 |
| Fulgent Genetics | 1,315 |
| Castle Biosciences | 883 |
| Burning Rock Biotech | 674 |
| FONAR | 535 |
| Biodesix | 334 |
| MDxHealth | 312 |
| Prenetics Global | 285 |
IMDX News
- 6 days ago - Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission - GlobeNewsWire
- 26 days ago - iMDx Announces $26.0 Million Registered Direct Offering - GlobeNewsWire
- 7 weeks ago - IMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant Monitoring - GlobeNewsWire
- 2 months ago - iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation - GlobeNewsWire
- 2 months ago - iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch - GlobeNewsWire
- 2 months ago - iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion - GlobeNewsWire
- 4 months ago - Insight Molecular Diagnostics Inc. (IMDX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch - GlobeNewsWire